Fda Without Out A News Today

We finally have a path forward for companies to compete for insulins. that wont even start until 2020. its going to be many years. the companies with the brand products are going to fight at every point. so the question is, should we be taking steps so that the rebates that the companies pay to the pbms get translated into lower prices forpatients and the pharmacy? theres a way to do it. the trump administration floated an idea. got a technical term, point of sale rebate. the math can be done an...